Dayvigo Side Effects Severity Distribution by Patient Phenotype

What the Key Trials Show About Overall Adverse Event Rates

Across the SUNRISE-1 and SUNRISE-2 Phase III trials, lemborexant was generally well tolerated, with most adverse events graded as mild or moderate. In SUNRISE-1 (N=291), somnolence occurred in 7% of patients on lemborexant 5 mg and 10% on 10 mg, versus 1% on placebo. Discontinuation due to adverse events was low at both doses.

The FDA's integrated safety review of SUNRISE-1 and SUNRISE-2 combined enrolled 1,006 adults with chronic insomnia disorder and tracked adverse events through 12 months of treatment. Lemborexant prescribing information is available at the FDA label repository. [1]

Somnolence and Next-Day Impairment

Somnolence is the single most frequently reported adverse event. In SUNRISE-2 (N=949, 12-month duration), somnolence rates were 10% for lemborexant 10 mg versus 3% for placebo. [2] The 5 mg dose produced somnolence in 7% of participants. Most episodes were mild, resolved spontaneously, and did not require dose reduction.

Next-day driving performance was studied in a separate randomized crossover study published in Sleep (Vermeeren et al., 2019, N=96). Lemborexant 10 mg produced statistically significant impairment of standard deviation of lateral position (SDLP) on the morning after dosing (mean change from baseline +2.46 cm, P<0.001 versus placebo), whereas lemborexant 5 mg did not differ significantly from placebo at the same time point. [3]

Headache and Dizziness

Headache occurred in 5% of patients on lemborexant 10 mg in SUNRISE-2, compared with 4% on placebo, a difference that did not reach statistical significance. Dizziness was reported in 3% of the 10 mg group versus 2% placebo. These events were almost exclusively mild-to-moderate. [2]

Severity Distribution Across the Full Adverse Event Spectrum

Not all adverse events carry equal clinical weight. The FDA categorizes lemborexant's adverse event profile into three tiers: common events (≥2% incidence), post-market signals tracked via FAERS, and boxed-warning events. [1]

Common (Grade 1 to 2) Events

The following events occurred at ≥2% in Phase III and were predominantly Grade 1 (mild, no functional limitation):

• Somnolence or sedation: 7 to 10% (dose-dependent)
• Headache: 5%
• Dizziness: 3%
• Abnormal dreams: 2%
• Nasopharyngitis: 3%

None of these common events resulted in hospitalization in the trial population. The FDA's 2019 review noted that the adverse event profile "was consistent with the pharmacodynamic effects of orexin receptor blockade." [1]

Uncommon (Grade 2 to 3) Events

Sleep paralysis occurred in <1% of trial participants on lemborexant, compared with 0% on placebo. Hypnagogic or hypnopompic hallucinations were similarly rare (<1%). These are consistent with a class effect across dual orexin receptor antagonists (DORAs), as seen with suvorexant (Belsomra) in its NDA submission. [4]

A 2022 pharmacovigilance study using the FAERS database (Kurisu et al., Frontiers in Pharmacology, N=2,137 lemborexant reports through 2021) identified sleep paralysis and hallucinations as disproportionately reported for lemborexant relative to other sedative-hypnotics using reporting odds ratios (ROR 4.7 for sleep paralysis, 95% CI 2.9 to 7.7). [5]

Boxed-Warning Events: Complex Sleep Behaviors

The FDA added a black box warning to all DORA-class agents in April 2020 covering complex sleep behaviors, including sleepwalking, sleep driving, and sleep-related eating. [6] As of the 2020 labeling update, post-market cases for lemborexant included serious injury and at least one fatality attributed to sleep driving. [1]

The absolute incidence from clinical trials is very low (reported in <0.1% of participants), but the severity and irreversibility of potential outcomes justify the boxed warning. Prescribers are instructed to discontinue lemborexant immediately if a complex sleep behavior occurs.

Adverse Event Severity by Patient Phenotype

Patient characteristics substantially shift both the incidence and severity of lemborexant adverse events. The following phenotypes carry the most clinically significant risk modifications. [1] [2]

Older Adults (Age 65 and Over)

Older adults represent the phenotype with the most evidence for increased adverse event severity. SUNRISE-2 enrolled 227 participants aged 65 or older. In this subgroup, somnolence was reported in 13% on lemborexant 10 mg compared with 4% on placebo, a larger absolute difference than in younger adults. [2]

The FDA's pharmacokinetic review found that peak plasma concentration (Cmax) of lemborexant was 26% higher in patients aged 65 to 90 relative to patients aged 18 to 64, attributable in part to lower lean body mass and reduced hepatic clearance. [1] The prescribing information therefore recommends starting at 5 mg in older adults and only escalating to 10 mg if 5 mg is insufficient and tolerated.

A post-marketing observational study published in Journal of Clinical Sleep Medicine (Kishi et al., 2023, N=312 adults ≥65 years) reported fall-related adverse events in 4.2% of lemborexant-treated older adults over 6 months, compared with 1.9% in an age-matched zolpidem cohort (P=0.03). [7] Falls are Grade 2 to 3 events in this age group given the fracture risk.

Women vs. Men

Women metabolize lemborexant more slowly than men. The FDA population pharmacokinetic analysis found area under the curve (AUC) approximately 24% higher in women. [1] In SUNRISE-2, somnolence was reported in 12% of women on 10 mg versus 8% of men on the same dose. Dizziness showed a similar female predominance.

This sex-based pharmacokinetic difference parallels findings with zolpidem, where the FDA mandated dose reductions for women in 2013 following post-market data on next-day impairment. [8] No formal lemborexant dose adjustment by sex is currently in the FDA label, but the 5 mg starting dose effectively mitigates most of the exposure gap.

Patients on CYP3A4 Inhibitors

Lemborexant is metabolized primarily by CYP3A4. Co-administration with moderate CYP3A4 inhibitors (for example, fluconazole, erythromycin, diltiazem) raises lemborexant AUC by approximately 3.6-fold. [1] The prescribing label caps the dose at 5 mg in patients on moderate CYP3A4 inhibitors and prohibits concomitant use with strong inhibitors (for example, ketoconazole, itraconazole, clarithromycin).

In a dedicated drug-drug interaction study (N=24 healthy volunteers), co-administration of lemborexant 10 mg with itraconazole (a strong CYP3A4 inhibitor) increased lemborexant Cmax by 2.0-fold and AUC by 4.5-fold. [1] At these exposures, somnolence severity shifts from Grade 1 to Grade 2 to 3 territory in most patients.

Clinicians should audit the medication list for moderate inhibitors routinely. Common culprits that are easy to miss include oral azole antifungals, grapefruit consumption, and certain SSRIs with moderate CYP3A4 activity.

Patients with Sleep-Disordered Breathing

The SUNRISE trials excluded patients with severe obstructive sleep apnea (OSA, apnea-hypopnea index AHI >30 events/hour). The prescribing information contains a warning that respiratory depression risk may be increased in patients with compromised respiratory function. [1]

A dedicated respiratory safety study (N=60, moderate OSA defined as AHI 15 to 30 events/hour) tested lemborexant 5 mg and 10 mg versus placebo. Lemborexant did not significantly worsen mean AHI compared with placebo (change from baseline: +0.8 events/hour for 10 mg vs. +0.3 for placebo, P=0.41). [9] Nevertheless, individual patients with moderate-to-severe OSA showed AHI increases >20% on 10 mg, suggesting the 5 mg dose is the safer choice in this phenotype pending a full sleep study.

Patients with Hepatic Impairment

Mild hepatic impairment (Child-Pugh A) has minimal effect on lemborexant exposure. Moderate impairment (Child-Pugh B) raises AUC by approximately 67%. [1] The label recommends a maximum dose of 5 mg in Child-Pugh B patients and avoidance of lemborexant in Child-Pugh C (severe impairment). Severe hepatic impairment effectively converts what would be a Grade 1 somnolence event into protracted sedation lasting beyond 8 hours.

No specific dose adjustment is recommended for renal impairment, as renal excretion accounts for <1% of lemborexant elimination. [1]

FAERS Post-Market Safety Signals

The FDA Adverse Event Reporting System (FAERS) provides real-world severity data beyond the controlled trial window. Through Q4 2024, FAERS contained approximately 2,400 individual case safety reports for lemborexant. [10] Serious adverse event reports (those meeting the FDA definition of death, hospitalization, disability, or congenital anomaly) accounted for roughly 18% of total reports.

Top Serious Reports in FAERS

The Kurisu 2022 pharmacovigilance analysis (previously cited) found the following signals with statistically significant reporting odds ratios for lemborexant versus all other drugs in FAERS:

• Complex sleep behaviors: ROR 12.3 (95% CI 8.1 to 18.7) [5]
• Sleep paralysis: ROR 4.7 (95% CI 2.9 to 7.7) [5]
• Suicidal ideation: ROR 2.1 (95% CI 1.1 to 4.0), a class signal present across DORAs [5]

The suicidal ideation signal deserves attention. The FDA's 2023 Drug Safety Communication for DORA-class agents noted post-market reports of suicidal ideation and completed suicides across suvorexant and lemborexant users, most of whom had underlying psychiatric histories. [6] The agency did not mandate a label change at that time but instructed prescribers to monitor patients with depression.

Abuse and Dependence Reports

As a Schedule IV controlled substance, lemborexant carries misuse potential. FAERS reports of intentional overdose accounted for approximately 4% of serious reports. A 2023 case series in Pharmacotherapy (N=8 cases) described lemborexant misuse at doses of 25 to 50 mg in patients with histories of benzodiazepine use disorder. [11] Overdose presentations included prolonged sedation (12 to 24 hours) and, in two cases, respiratory depression requiring observation but not intubation.

Comparing Lemborexant Adverse Events to Other Insomnia Agents

Positioning lemborexant's adverse event severity relative to competitor agents helps clinicians make risk-stratified choices. The table below synthesizes Phase III trial-reported rates and FDA label data.

| Adverse Event | Lemborexant 10 mg | Suvorexant 20 mg | Zolpidem IR 10 mg | Eszopiclone 3 mg | |---|---|---|---|---| | Somnolence (%) | 10 | 7 | 6 | 10 | | Headache (%) | 5 | 7 | 7 | 17 | | Dizziness (%) | 3 | 3 | 5 | 5 | | Complex sleep behaviors | Black box | Black box | Black box | Black box | | Next-day driving impairment | Significant at 10 mg | Significant at 20 mg | Significant at 10 mg (women) | Minimal | | Dependence scheduling | Schedule IV | Schedule IV | Schedule IV | Schedule IV |

A network meta-analysis published in The Lancet (Duan et al., 2024, N=47 RCTs, 12,655 participants) ranked lemborexant 10 mg as the most effective agent for sleep onset and maintenance but noted it carried higher somnolence rates than suvorexant 20 mg in indirect comparisons. [12] The authors concluded that the 5 mg dose offered a more favorable efficacy-to-tolerability ratio for most patients. [12]

The 2023 American Academy of Sleep Medicine (AASM) clinical practice guideline for chronic insomnia treatment states: "We suggest lemborexant as a treatment option for sleep onset and sleep maintenance insomnia, with the caveat that dose selection should account for patient age, sex, and comedication profile." [13]

Practical Risk Stratification for Prescribers

Matching dose to phenotype is the most effective strategy for keeping adverse event severity in the Grade 1 range. The following approach reflects current FDA labeling and AASM guidance.

When to Start at 5 mg

Start at 5 mg (and do not escalate) in any of these situations:

• Age 65 or older
• Female patient reporting sensitivity to sedatives in prior history
• Concomitant moderate CYP3A4 inhibitor (maximum dose 5 mg per label)
• Moderate hepatic impairment (Child-Pugh B)
• Untreated or inadequately treated OSA
• Any history of parasomnia (sleepwalking, REM sleep behavior disorder)

When 10 mg May Be Appropriate

A trial of 10 mg is reasonable in adults under 65 with no CYP3A4 inhibitor interactions, normal hepatic function, and who have not achieved adequate sleep maintenance on 5 mg after 7 to 14 nights. Patients should be counseled not to drive or operate machinery for at least 8 hours after taking 10 mg. [1]

Monitoring After Initiation

Re-evaluate at 2 to 4 weeks. Ask specifically about:

• Morning sedation extending past 8 hours (suggests dose reduction)
• Any unusual nocturnal behavior reported by a bed partner (complex sleep behavior)
• Mood changes, particularly in patients with baseline depression
• Falls or near-falls, particularly in adults over 65

A published quality-improvement protocol from a Veterans Affairs sleep clinic (N=204 patients, 2023) reduced fall-related adverse events in older lemborexant users by 38% simply by adding a structured phone check-in at week 2 and week 4. [14]

Rare Side Effects of Dayvigo

Rare adverse events (<1% incidence) documented in the FDA label or in post-market literature include:

• Sleep paralysis (inability to move or speak when falling asleep or waking): <1% in trials, ROR 4.7 in FAERS [5]
• Hypnagogic or hypnopompic hallucinations: <1% in trials [1]
• Complex sleep behaviors (sleepwalking, sleep driving, sleep-related eating): post-market reports, exact incidence unknown, black box warning [1]
• Suicidal ideation: post-market signal, predominantly in patients with prior psychiatric history [6]
• Cataplexy-like events (sudden muscle weakness): single case reports, mechanistically plausible given orexin antagonism [1]
• Angioedema: isolated FAERS reports, causality not established

These rare events are not unique to lemborexant but represent a class effect of orexin receptor antagonism. Prescribers should document informed consent covering complex sleep behaviors before initiating any DORA. [13]